Sequencing MS therapies: 2 studies


Report from the 1st Congress of the European Academy of Neurology, Berlin, Germany, June 20-23, 2015 – Few studies have examined the feasibility of switching MS patients from one higher-efficacy therapy to another. In the TOFINGO and ENIGM (Enquête Nationale sur l’Introduction du Fingolimod en Relais au Natalizumab) prospective studies, disease reactivation was generally well controlled after switching from natalizumab to fingolimod, most notably when the washout period did not exceed 12 weeks (Kappos et al. Neurology 2015; epublished May 29, 2015; Cohen et al. JAMA Neurol 2014;71:436-441).

It takes 30 seconds

Recommend to a Colleague

Related Posts

Go back to home page